Udenyca Generic Name & Formulations
Legal Class
General Description
Pharmacological Class
How Supplied
Single-dose prefilled syringe—1; Single-dose prefilled autoinjector—1
Manufacturer
Generic Availability
Mechanism of Action
Udenyca Indications
Indications
To decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anticancer drugs associated with clinically significant incidence of febrile neutropenia. To increase survival in patients acutely exposed to myelosuppressive doses of radiation.
Limitations of Use
Udenyca Dosage and Administration
Adults and Children
See full labeling. ≥45kg: On myelosuppressive chemotherapy: 6mg SC once per chemotherapy cycle. Do not give between 14 days before and 24 hours after chemotherapy. Hematopoietic subsyndrome of acute radiation syndrome: 6mg SC each for 2 doses, given 1 week apart. Administer the 1st dose as soon as possible after suspected or confirmed exposure to radiation levels >2 gray (Gy). Both: Pediatrics (31–44kg): 4mg; (21–30kg): 2.5mg; (10–20kg): 1.5mg; (<10kg): 0.1mg/kg. Direct administration of prefilled syringe with doses <6mg is not recommended. Prefilled autoinjector: not suitable for use in pediatrics <45kg.
Udenyca Contraindications
Not Applicable
Udenyca Boxed Warnings
Not Applicable
Udenyca Warnings/Precautions
Warnings/Precautions
Udenyca Pharmacokinetics
Elimination
Udenyca Interactions
Not Applicable
Udenyca Adverse Reactions
Adverse Reactions
Udenyca Clinical Trials
See Literature
Udenyca Note
Not Applicable
Udenyca Patient Counseling
See Literature